LIDDS AB (publ) (LIDDS.ST)
SEK 0.03
(-15.5%)
SEK 0.03
(-15.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -40.2 Million SEK | -8.36% |
| 2022 | -37.1 Million SEK | 0.45% |
| 2021 | -37.27 Million SEK | -15.24% |
| 2020 | -32.34 Million SEK | -35.7% |
| 2019 | -23.83 Million SEK | -535.94% |
| 2018 | -3.74 Million SEK | 43.81% |
| 2017 | -6.66 Million SEK | -0.53% |
| 2016 | -6.63 Million SEK | 15.11% |
| 2015 | -7.81 Million SEK | -10.64% |
| 2014 | -7.06 Million SEK | -81.59% |
| 2013 | -3.88 Million SEK | -4.79% |
| 2012 | -3.71 Million SEK | -6.61% |
| 2011 | -3.48 Million SEK | -85.69% |
| 2010 | -1.87 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.39 Million SEK | -47860.0% |
| 2024 Q1 | -5000.00 SEK | 99.97% |
| 2023 Q1 | -9.68 Million SEK | -3.53% |
| 2023 Q3 | -4.53 Million SEK | 38.6% |
| 2023 Q4 | -18.66 Million SEK | -311.69% |
| 2023 Q2 | -7.38 Million SEK | 23.75% |
| 2023 FY | -40.2 Million SEK | -8.36% |
| 2022 Q2 | -9.91 Million SEK | -1.62% |
| 2022 Q1 | -9.75 Million SEK | -9.35% |
| 2022 FY | -37.1 Million SEK | 0.45% |
| 2022 Q4 | -9.35 Million SEK | -15.64% |
| 2022 Q3 | -8.08 Million SEK | 18.39% |
| 2021 Q4 | -8.91 Million SEK | -14.3% |
| 2021 Q3 | -7.8 Million SEK | 20.07% |
| 2021 Q2 | -9.76 Million SEK | 9.5% |
| 2021 Q1 | -10.78 Million SEK | 13.78% |
| 2021 FY | -37.27 Million SEK | -15.24% |
| 2020 Q2 | -5.29 Million SEK | 33.49% |
| 2020 Q4 | -12.51 Million SEK | -90.64% |
| 2020 FY | -32.34 Million SEK | -35.7% |
| 2020 Q1 | -7.96 Million SEK | 47.38% |
| 2020 Q3 | -6.56 Million SEK | -23.88% |
| 2019 Q1 | -2.52 Million SEK | 48.89% |
| 2019 FY | -23.83 Million SEK | -535.94% |
| 2019 Q4 | -15.13 Million SEK | -441.32% |
| 2019 Q3 | -2.79 Million SEK | 17.08% |
| 2019 Q2 | -3.37 Million SEK | -33.54% |
| 2018 Q1 | -1.96 Million SEK | 11.18% |
| 2018 FY | -3.74 Million SEK | 43.81% |
| 2018 Q2 | -2.24 Million SEK | -14.31% |
| 2018 Q4 | -4.94 Million SEK | -191.46% |
| 2018 Q3 | 5.4 Million SEK | 340.62% |
| 2017 Q1 | -1.83 Million SEK | 13.76% |
| 2017 FY | -6.66 Million SEK | -0.53% |
| 2017 Q2 | -1.18 Million SEK | 35.25% |
| 2017 Q3 | -1.44 Million SEK | -21.77% |
| 2017 Q4 | -2.21 Million SEK | -53.24% |
| 2016 Q1 | -1.45 Million SEK | 10.74% |
| 2016 Q4 | -2.12 Million SEK | -32.13% |
| 2016 Q3 | -1.6 Million SEK | -10.84% |
| 2016 FY | -6.63 Million SEK | 15.11% |
| 2016 Q2 | -1.44 Million SEK | 0.55% |
| 2015 Q1 | -2.17 Million SEK | -22.78% |
| 2015 FY | -7.81 Million SEK | -10.64% |
| 2015 Q4 | -1.63 Million SEK | 9.97% |
| 2015 Q3 | -1.81 Million SEK | 17.25% |
| 2015 Q2 | -2.19 Million SEK | -0.55% |
| 2014 Q1 | -1.33 Million SEK | -26.8% |
| 2014 FY | -7.06 Million SEK | -81.59% |
| 2014 Q4 | -1.77 Million SEK | 6.94% |
| 2014 Q3 | -1.9 Million SEK | 6.61% |
| 2014 Q2 | -2.04 Million SEK | -52.5% |
| 2013 Q4 | -1.05 Million SEK | 18.96% |
| 2013 Q1 | -1.17 Million SEK | 0.0% |
| 2013 Q2 | -1.38 Million SEK | -17.3% |
| 2013 Q3 | -1.3 Million SEK | 5.78% |
| 2013 FY | -3.88 Million SEK | -4.79% |
| 2012 FY | -3.71 Million SEK | -6.61% |
| 2011 FY | -3.48 Million SEK | -85.69% |
| 2010 FY | -1.87 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 91.376% |
| AcouSort AB (publ) | -17.08 Million SEK | -135.274% |
| Active Biotech AB (publ) | -45.8 Million SEK | 12.214% |
| Alzinova AB (publ) | -16.48 Million SEK | -143.968% |
| Amniotics AB (publ) | -30.87 Million SEK | -30.243% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -213.424% |
| BioArctic AB (publ) | 229.24 Million SEK | 117.538% |
| Camurus AB (publ) | 431.44 Million SEK | 109.319% |
| Cantargia AB (publ) | -280.02 Million SEK | 85.642% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -90.631% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -145.189% |
| Genovis AB (publ.) | 61.5 Million SEK | 165.376% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 64.521% |
| Mendus AB (publ) | -101.61 Million SEK | 60.435% |
| Kancera AB (publ) | -64.88 Million SEK | 38.039% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 846.491% |
| Lipum AB (publ) | -37.17 Million SEK | -8.145% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -231.514% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 430.397% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -124.652% |
| NextCell Pharma AB | -41.95 Million SEK | 4.18% |
| OncoZenge AB (publ) | -15.9 Million SEK | -152.836% |
| Saniona AB (publ) | -95.81 Million SEK | 58.036% |
| Simris Alg AB (publ) | -37.3 Million SEK | -7.776% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 87.07% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 89.642% |
| Xintela AB (publ) | -54.08 Million SEK | 25.659% |
| Ziccum AB (publ) | -21.41 Million SEK | -87.773% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -8.457% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 77.622% |
| CombiGene AB (publ) | -35.66 Million SEK | -12.731% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 73.523% |
| Intervacc AB (publ) | -102.85 Million SEK | 60.909% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 83.826% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -9079.452% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -143.334% |
| Corline Biomedical AB | -1.8 Million SEK | -2122.554% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 77.392% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 29.241% |
| Aptahem AB (publ) | -11.11 Million SEK | -261.797% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 67.33% |
| Fluicell AB (publ) | -26.55 Million SEK | -51.412% |
| Biovica International AB (publ) | -124.82 Million SEK | 67.79% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 4.777% |
| Abliva AB (publ) | -95.5 Million SEK | 57.903% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 87.701% |
| 2cureX AB (publ) | -32.51 Million SEK | -23.642% |
| I-Tech AB | 20.2 Million SEK | 299.01% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.166% |
| Cyxone AB (publ) | -22.98 Million SEK | -74.892% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 56.011% |
| Biosergen AB | -27.03 Million SEK | -48.707% |
| Nanologica AB (publ) | -75.15 Million SEK | 46.504% |
| SynAct Pharma AB | -215.81 Million SEK | 81.37% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 8.735% |
| BioInvent International AB (publ) | -330.3 Million SEK | 87.828% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -69.381% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 83.86% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -304.894% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 63.211% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -244.288% |